Page 6,803«..1020..6,8026,8036,8046,805..6,8106,820..»

Izon granted core patents for elastomeric nanopore tech

Posted: Published on June 7th, 2012

Izon Science granted core patents for elastomeric nanopore technology CHRISTCHURCH, New Zealand, 7 June 2012 Nanotechnology instrument manufacturer Izon Science today announced core patents for its nano and bio particle analysis platform. The United States Patent and Trademark Office (USPTO) has accepted Izon Science Patent No. 11/721047 for an invention for detecting, measuring and controlling particles. The patent covers the novel elastomeric size-tunable nanopores used in Izon Sciences qNano and qViro instruments. The Australian Patent Office has also accepted Izon Science Patent No. 2005315729 for the same core technology. Izon Science has also been granted a patent for its analysis platform by the UK Intellectual Property Office. UK Patent No. 2477287 (formerly Application No. 1001311.8) for Control of particle flow in an aperture and relates to the use of combined pressure and voltage. This follows on from the prior award of the core patent in 2006 (GB2421303, 12 November 2006). Acceptance of these patents is a major milestone for the company. Were now selling our instrumentation in over 30 countries and are rapidly expanding our patent portfolio, core measurement capabilities and R&D capability, says Hans van der Voorn, Executive Chairman of Izon Science. Van der Voorn says the company is … Continue reading →

Comments Off on Izon granted core patents for elastomeric nanopore tech

Neil Riordan PhD – Stem Cell Therapy for Spinal Cord Injury (Part 3 of 5) || Stem Cell Treatments – Video

Posted: Published on June 7th, 2012

06-06-2012 13:09 Mesenchymal stem cell homing to tissue damage, umbilical cord stem cells historically used for anti-aging, mesenchymal stem cells role in immune system modulation, inflammation reduction and stimulating tissue regeneration, donor stem cell safety and testing, the role of HLA matching in donated umbilical cord-derived stem cells, umbilical cord blood safety data and historical use in blood transfusions, allogeneic stem cell persistence in human mothers. Treatment information at More information on Dr. Riordan at See more here: Neil Riordan PhD - Stem Cell Therapy for Spinal Cord Injury (Part 3 of 5) || Stem Cell Treatments - Video … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Neil Riordan PhD – Stem Cell Therapy for Spinal Cord Injury (Part 3 of 5) || Stem Cell Treatments – Video

Does Crestor sap a man's sex drive?

Posted: Published on June 7th, 2012

Q. I am a very active Army physical training instructor. I am 45 years old and have always had a great sex drive until I started taking Crestor six months ago to lower my cholesterol. My sex drive has totally disappeared. I am unable to maintain an erection and feel tired all the time. It has been causing me a great deal of stress and anguish. Is Crestor causing my erectile dysfunction and libido problems? A. Sexual side effects have been reported with some statins, such as lovastatin, pitavastatin (Livalo) and simvastatin. The official prescribing information for Crestor, however, makes no mention of low libido or erectile dysfunction. There is reason to believe that all statins may have a negative impact on sexual function by lowering testosterone levels (Journal of Sexual Medicine, April 2010). Cholesterol is a building block for testosterone, so it is not surprising that cholesterol-lowering drugs might have an impact on this hormone. Results from French research suggest that such drugs may trigger or worsen erectile dysfunction (Drug Safety, July 2009). Ask your doctor if there's another way to control cholesterol. If not, a test for testosterone or an ED drug might be helpful. Q. To prevent … Continue reading →

Posted in Erectile Dysfunction | Comments Off on Does Crestor sap a man's sex drive?

Studies show new drug to be effective in treating skin cancer, Stanford researchers say

Posted: Published on June 7th, 2012

Public release date: 6-Jun-2012 [ | E-mail | Share ] Contact: Tracie White traciew@stanford.edu 650-723-7628 Stanford University Medical Center STANFORD, Calif. A new drug has been shown to be effective in treating and preventing the most common cancer in the United States: basal cell carcinoma skin cancer, according to a new study in the New England Journal of Medicine to be published June 7. The drug, vismodegib (trade name: Erivedge), was tested in a clinical trial in patients with Gorlin syndrome, a rare disease in which individuals have tens to hundreds of disfiguring basal cell carcinoma tumors. The findings are being released in conjunction with two other papers in the same journal issue that show the effectiveness of vismodegib in treating BCCs that are advanced or metastatic. All three articles include authors from the Stanford University School of Medicine. "It is a landmark day for patients with basal cell carcinoma and all those involved in their care the greatest advance in therapy yet seen for this disease," writes John Lear, MD, in an accompanying editorial. Lear is a consultant dermatologist at Manchester Royal Infirmary and the Dermatology Centre of Hope Hospital in Manchester, UK. The research is being published five … Continue reading →

Posted in Cell Medicine | Comments Off on Studies show new drug to be effective in treating skin cancer, Stanford researchers say

Some factors that impact islet transplantation explored in Cell Transplantation papers

Posted: Published on June 7th, 2012

Public release date: 6-Jun-2012 [ | E-mail | Share ] Contact: David Eve celltransplantation@gmail.com Cell Transplantation Center of Excellence for Aging and Brain Repair Tampa, Fla. (June 6, 2012) Two studies appearing in the current issue of Cell Transplantation (21:2/3), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/, evaluate the transplantation potential and success of islet cells derived from pancreatic tissues, in addition to a clinical study that reports the occurrence of adverse events. Fresh islets are better than cultured islets A team of researchers from Baylor Research Institute, Texas and the University Graduate School of Medicine in Okayama, Japan has found that islet cells freshly retrieved from the pancreas are superior to islet cells that have been cultured. "Isolated islet cells deteriorate rapidly in culture," said study lead author Hirofumi Noguchi. "In our study we compared human fresh islet cells to cultured islets with in vitro and in vivo assays. Human islets, fresh and cultured, were transplanted into diabetic nude mice." The researchers found that cultured islet yield decreased significantly after 24, 48 and 72 hours. The cultured islets showed a 24 percent loss after 48 hours. By comparison, the blood glucose levels of the diabetic mice were significantly lower with … Continue reading →

Posted in Cell Medicine | Comments Off on Some factors that impact islet transplantation explored in Cell Transplantation papers

New drug found effective against rare form of basal cell skin cancer

Posted: Published on June 7th, 2012

ScienceDaily (June 6, 2012) A clinical study has demonstrated that a new drug, a targeted molecular therapy called vismodegib (trade name Erivedge), can dramatically shrink basal cell skin cancers and prevent the formation of new ones, in patients with basal cell nevus syndrome (BCNS). This rare genetic condition causes dozens, and sometimes hundreds or thousands, of skin cancers on each patient's body. The primary treatment option is surgical removal. These study results are significant as they indicate the possibility of an alternative treatment with oral medication; although side effects remain a consideration. The phase II clinical study, led by researchers at NewYork-Presbyterian Hospital/Columbia University Medical Center (NYPH/CUMC) and Children's Hospital of Oakland Research Institute (CHORI), was published June 6 in the online edition of the New England Journal of Medicine. "In its current formulation, vismodegib is appropriate only for BCNS patients with very large numbers of basal cell skin cancers. Still, this is a huge step forward, pointing to the day when we can offer every one of these patients an alternative to repeated surgery, which can be disfiguring and burdensome," said study co-leader David R. Bickers, MD, the Carl Truman Nelson Professor and chairman of dermatology at CUMC and … Continue reading →

Posted in Cell Therapy | Comments Off on New drug found effective against rare form of basal cell skin cancer

A place to recover: Lorain ponders permit for veterans house (with video)

Posted: Published on June 7th, 2012

By RICHARD PAYERCHIN rpayerchin@MorningJournal.com @MJ_JournalRick Morning Journal/Richard Payerchin House Manager Ed Wells, the Rev. Steve Paliwoda and Alan Revercomb Sr. stand outside Sobering Centers first home on East 33rd Street in Lorain. They hope to provide a safe, sober home for veterans who want to end alcohol and drug dependency before moving to other residences or, in the future, Valor Home Lorain County. LORAIN City officials are mulling over a zoning variance for a home where veterans can live while overcoming drug and alcohol addictions. Sobering Centers Inc. was formed in anticipation of the Valor Home Lorain County veterans shelter and resource center opening at the St. Joseph Community Center in Lorain. Since Valor Home is not planning to accept residents with chemical dependency, the nonprofit Sobering Centers Inc. was formed as a place where veterans can live while they recover. Were veterans helping veterans, its as simple as that, said Alan L. Revercomb Sr., president of the organization. Sobering Centers is seeking a conditional use variance to use at a two-story home at 2538 E. 33rd St. The Lorain Zoning Board of Appeals yesterday voted to delay a decision for 30 days because of legal questions about the issue. … Continue reading →

Posted in Drug Dependency | Comments Off on A place to recover: Lorain ponders permit for veterans house (with video)

Treatment eases arthritis pain in dogs

Posted: Published on June 7th, 2012

A local veterinary clinic recently added a cuttingedge treatment. Dr. Tina Gemeinhardt, owner of Tsawwassen Animal Hospital, is excited to be offering stem cell therapy to animals suffering from arthritis and joint issues. "I'm excited about trying to bring some relief to dogs that are living in pain," she said. The therapy, which uses stem cells harvested from fat that is surgically removed from the dog, is, in most cases, able to offer relief from the pain and stiffness associated with Gemeinhardt said once it's determined the therapy is the right course of treatment for an animal, body fat is surgically removed and sent to a lab in California where the stem cells are harvested. The harvested stem cells are then sent back to the vet clinic within 48 hours and injected into the joints in question. Gemeinhardt, who added the treatment to the clinic's list of services earlier this year, said it's not quite clear exactly how the stem cells work. "Stem cells seem to inherently know what needs to be done in that area," she said. The treatment is not a cure-all - the arthritis is still there but the symptoms are lessened - and it does not … Continue reading →

Comments Off on Treatment eases arthritis pain in dogs

Duchenne Dads to Climb Tallest Peak in the Great Smoky Mountains to Raise Funds to Find a Cure for Duchenne Muscular …

Posted: Published on June 7th, 2012

CHATTANOOGA, Tenn.--(BUSINESS WIRE)-- Four dads whose sons have Duchenne muscular dystrophy will climb Clingmans Dome, the highest peak in the Smoky Mountains, on June 30 as part of the annual Climb to CureDuchenne: Pick Your Peak event happening nationwide. People across the country are climbing a mountain, hill or tall building to increase awareness and raise funds to find a cure for Duchenne muscular dystrophy. CureDuchenne, a nonprofit organization that raises awareness and funds research to cure Duchenne muscular dystrophy, organized the event. Todd Crawford, Nick Ware, Jimmy Dotson, and Brad Nance, are Duchenne dads climbing for their sons Mackenzie, 12, Alex, 16, Luke, 7 and Caleb, 6. It is statistically remarkable that four dads, who all work in the Chattanooga information technology industry, all have sons living with Duchenne, a rare and devastating muscle disease that affects 1 in 3,500 boys. Crawford and Dotson both work at Unum; Ware works for Lawson and is a contractor at Unum; and Nance works for Northwest Georgia Bank in the IT department. Crawford created a Climb to CureDuchenne team called CALM Dads, which represents the first initial of each of their sons names, to raise much needed funding for scientific research to … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on Duchenne Dads to Climb Tallest Peak in the Great Smoky Mountains to Raise Funds to Find a Cure for Duchenne Muscular …

Catabasis Pharmaceuticals to Present at Parent Project Muscular Dystrophy (PPMD) Annual Connect Conference

Posted: Published on June 7th, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Catabasis Pharmaceuticals, a clinical stage biopharmaceutical company dedicated to the discovery and development of innovative, effective and safe medicines for the treatment of inflammatory and metabolic diseases, today announced that Michael Jirousek, Ph.D., chief scientific officer and co-founder of Catabasis, will present at the Parent Project Muscular Dystrophy (PPMD) Annual Connect Conference to be held June 28-July 1, 2012 at the Harbor Beach Marriott Hotel in Ft. Lauderdale, Fla. Dr. Jirousek will present in a research panel focused on the role of inflammation and fibrosis in Duchenne Muscular Dystrophy (DMD) at 4:00 p.m. ET on Saturday, June 30, 2012. This interactive panel is part of a special three-part series being presented at this years meeting focused on clinical trials and the future of this research and treatment for DMD. These panels will feature commentary and insight from parents whose children are or were participating in trials, clinicians who run the trials and from the industry leaders developing these trials. Dr. Jirousek has also been invited to be a guest speaker in a webinar hosted by PPMD on June 6, 2012 at 1 p.m. ET to discuss the new approaches to treating inflammation in DMD. The webinar can … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on Catabasis Pharmaceuticals to Present at Parent Project Muscular Dystrophy (PPMD) Annual Connect Conference

Page 6,803«..1020..6,8026,8036,8046,805..6,8106,820..»